Arvinas Stock
Arvinas is a pharmaceutical company focused on protein degradation approaches to develop novel drugs to treat cancer and other diseases.
Sign up today and learn more about Arvinas Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Arvinas Stock
Arvinas is a pharmaceutical company focused on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Central to Arvinas’ proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body. This strategy of degradation versus protein inhibition holds several advantages including the potential to target proteins that are not currently ‘druggable’ using a small molecule approach.
Funding History
| September 2013 | $15.0M |
|---|---|
| October 2015 | $41.6M |
| April 2018 | $55.0M |
Management
CEO
Timothy Shannon
Founder
Craig M. Crew
Press
Hartford Courant - Apr, 4 2018
New Haven's Arvinas Raises $55M To Begin Cancer TrialsYale Daily News (blog) - Jan, 25 2018
Yale startup partners with big pharma- Jan, 19 2018
Arvinas to expand at Science Park, add 30 jobsMedCity News - Jan, 4 2018
Pfizer and Arvinas sign $830M drug development deal that target proteins causing diseaseEndpoints News - Nov, 15 2017
Genentech inks $650M deal with protein degradation pioneer ArvinasEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
